Drug Type Bispecific antibody |
Synonyms ES 014, ES-014 |
Target |
Mechanism CD39 inhibitors(Ectonucleoside triphosphate diphosphohydrolase 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Elpiscience Biopharma Ltd.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date20 Aug 2024 |
Sponsor / Collaborator |
Start Date21 Apr 2023 |
Sponsor / Collaborator Elpiscience Biopharma Ltd.Startup |
Start Date21 Feb 2023 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 20 Aug 2024 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | CN | 21 Feb 2023 | |
Metastatic Solid Tumor | Phase 1 | CN | 21 Feb 2023 | |
Solid tumor | Phase 1 | US | Elpiscience Biopharma Ltd.Startup | 09 May 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |